133 related articles for article (PubMed ID: 38567708)
1. New insights into the anticancer therapeutic potential of icaritin and its synthetic derivatives.
Reyes-Hernández OD; Figueroa-González G; Quintas-Granados LI; Hernández-Parra H; Peña-Corona SI; Cortés H; Kipchakbayeva A; Mukazhanova Z; Habtemariam S; Leyva-Gómez G; Büsselberg D; Sharifi-Rad J
Drug Dev Res; 2024 Apr; 85(2):e22175. PubMed ID: 38567708
[TBL] [Abstract][Full Text] [Related]
2. Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival.
Qin SK; Li Q; Ming Xu J; Liang J; Cheng Y; Fan Y; Jiang J; Ye H; Tao H; Li L; Zheng L; Wei Z; Li S; Meng K; Ye B; Sun Y
Cancer Sci; 2020 Nov; 111(11):4218-4231. PubMed ID: 32889778
[TBL] [Abstract][Full Text] [Related]
3. Molecular and cellular basis of the anticancer activity of the prenylated flavonoid icaritin in hepatocellular carcinoma.
Bailly C
Chem Biol Interact; 2020 Jul; 325():109124. PubMed ID: 32437694
[TBL] [Abstract][Full Text] [Related]
4. Icaritin Induces Anti-tumor Immune Responses in Hepatocellular Carcinoma by Inhibiting Splenic Myeloid-Derived Suppressor Cell Generation.
Tao H; Liu M; Wang Y; Luo S; Xu Y; Ye B; Zheng L; Meng K; Li L
Front Immunol; 2021; 12():609295. PubMed ID: 33717093
[TBL] [Abstract][Full Text] [Related]
5. First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers.
Fan Y; Li S; Ding X; Yue J; Jiang J; Zhao H; Hao R; Qiu W; Liu K; Li Y; Wang S; Zheng L; Ye B; Meng K; Xu B
BMC Cancer; 2019 Mar; 19(1):279. PubMed ID: 30922248
[TBL] [Abstract][Full Text] [Related]
6. Icaritin promotes apoptosis and inhibits proliferation by down-regulating AFP gene expression in hepatocellular carcinoma.
Li H; Liu Y; Jiang W; Xue J; Cheng Y; Wang J; Yang R; Zhang X
BMC Cancer; 2021 Mar; 21(1):318. PubMed ID: 33765973
[TBL] [Abstract][Full Text] [Related]
7. A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway.
Zhao H; Guo Y; Li S; Han R; Ying J; Zhu H; Wang Y; Yin L; Han Y; Sun L; Wang Z; Lin Q; Bi X; Jiao Y; Jia H; Zhao J; Huang Z; Li Z; Zhou J; Song W; Meng K; Cai J
Oncotarget; 2015 Oct; 6(31):31927-43. PubMed ID: 26376676
[TBL] [Abstract][Full Text] [Related]
8. Nanomedicine-boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma.
Lu Y; Gao Y; Yang H; Hu Y; Li X
Mil Med Res; 2022 Dec; 9(1):69. PubMed ID: 36503490
[TBL] [Abstract][Full Text] [Related]
9. Anticancer agent icaritin induces apoptosis through caspase-dependent pathways in human hepatocellular carcinoma cells.
Sun L; Peng Q; Qu L; Gong L; Si J
Mol Med Rep; 2015 Apr; 11(4):3094-100. PubMed ID: 25434584
[TBL] [Abstract][Full Text] [Related]
10. Icaritin inhibits JAK/STAT3 signaling and growth of renal cell carcinoma.
Li S; Priceman SJ; Xin H; Zhang W; Deng J; Liu Y; Huang J; Zhu W; Chen M; Hu W; Deng X; Zhang J; Yu H; He G
PLoS One; 2013; 8(12):e81657. PubMed ID: 24324713
[TBL] [Abstract][Full Text] [Related]
11. Icaritin with autophagy/mitophagy inhibitors synergistically enhances anticancer efficacy and apoptotic effects through PINK1/Parkin-mediated mitophagy in hepatocellular carcinoma.
Luo P; An Y; He J; Xing X; Zhang Q; Liu X; Chen Y; Yuan H; Chen J; Wong YK; Huang J; Gong Z; Du Q; Xiao W; Wang J
Cancer Lett; 2024 Apr; 587():216621. PubMed ID: 38242198
[TBL] [Abstract][Full Text] [Related]
12. CD8
Xu C; Lu X; Liu W; Chen A; Meng G; Zhang H; Li B; Zhang Y; Wu J; Wei J
J Transl Med; 2018 May; 16(1):132. PubMed ID: 29784005
[TBL] [Abstract][Full Text] [Related]
13. Icaritin Exacerbates Mitophagy and Synergizes with Doxorubicin to Induce Immunogenic Cell Death in Hepatocellular Carcinoma.
Yu Z; Guo J; Hu M; Gao Y; Huang L
ACS Nano; 2020 Apr; 14(4):4816-4828. PubMed ID: 32188241
[TBL] [Abstract][Full Text] [Related]
14. Icaritin inhibits PD-L1 expression by Targeting Protein IκB Kinase α.
Mo D; Zhu H; Wang J; Hao H; Guo Y; Wang J; Han X; Zou L; Li Z; Yao H; Zhu J; Zhou J; Peng Y; Li J; Meng K
Eur J Immunol; 2021 Apr; 51(4):978-988. PubMed ID: 33354776
[TBL] [Abstract][Full Text] [Related]
15. Icaritin induces apoptosis of HepG2 cells via the JNK1 signaling pathway independent of the estrogen receptor.
He J; Wang Y; Duan F; Jiang H; Chen MF; Tang SY
Planta Med; 2010 Nov; 76(16):1834-9. PubMed ID: 20560114
[TBL] [Abstract][Full Text] [Related]
16. Icaritin promotes tumor T-cell infiltration and induces antitumor immunity in mice.
Hao H; Zhang Q; Zhu H; Wen Y; Qiu D; Xiong J; Fu X; Wu Y; Meng K; Li J
Eur J Immunol; 2019 Dec; 49(12):2235-2244. PubMed ID: 31465113
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Structure-Activity Analysis of Icaritin Derivatives as Potential Tumor Growth Inhibitors of Hepatocellular Carcinoma Cells.
Li J; Shen S; Liu Z; Zhao H; Liu S; Liu Q; Yao GD; Song SJ
J Nat Prod; 2023 Feb; 86(2):290-306. PubMed ID: 36745506
[TBL] [Abstract][Full Text] [Related]
18. Identification of sphingosine kinase 1 (SphK1) as a primary target of icaritin in hepatocellular carcinoma cells.
Lu PH; Chen MB; Liu YY; Wu MH; Li WT; Wei MX; Liu CY; Qin SK
Oncotarget; 2017 Apr; 8(14):22800-22810. PubMed ID: 28206952
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effects of icaritin and the molecular mechanisms.
Zhang C; Sui X; Jiang Y; Wang X; Wang S
Discov Med; 2020; 29(156):5-16. PubMed ID: 32598859
[TBL] [Abstract][Full Text] [Related]
20. Icaritin Sensitizes Human Glioblastoma Cells to TRAIL-Induced Apoptosis.
Han H; Xu B; Hou P; Jiang C; Liu L; Tang M; Yang X; Zhang Y; Liu Y
Cell Biochem Biophys; 2015 Jun; 72(2):533-42. PubMed ID: 25577511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
